Elicio Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is ELTX moving today?
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ELTX.
ELTX insider activity
Elicio Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $2K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-10 | 2025-12-09 | DeMuth Peter | Insider | buy | $4.41 | 362 | 743 | $2K | SEC Form 4 |
ELTX contract awards, year to date.
Public federal awards linked to this ticker.
ELTX lobbying filings, year to date.
Registered lobbying filings matched to Elicio Therapeutics, Inc. Common Stock.